Replies to post #158861 on Anavex Life Sciences Corp (AVXL)

[polarbear77]

Excellent points, and this seemed also on topic:

http://cdn.intechopen.com/pdfs-wm/48230.pdf
Published 2015

Excerpts:
“Mitochondria are sub-cellular organelles that play pivotal roles essential for energy (ATP) production, metabolism, and homeostasis.”

“Investigation associating an elevated oxidant state with mitochondrial damage, aging dictates, and degenerative disease the need for a better under- standing of how and when pharmacological manipulation of mitochondrial function prepares most therapeutic benefit [4].

Mitochondria carry out vital biochemical functions essential for cells such as homeostasis calcium, cell death and survival, in addition to ATP production.”

“Furthermore, mitochondria are active players in cellular calcium homeostasis. Mitochondrial Ca2+ accumulation regulates functions as diverse as aerobic metabolism and induction of cell death. Finally, mutations in mitochondrial DNA (mtDNA) are responsible for many mitochondrial metabolic disorders, and are thought to contribute to aging by promoting apoptosis.”

“...degenerative and aging diseases are associated with an elevated oxidant state that may associate mitochondrial damage. In these cases, antioxidants targeting mitochondria are hoped to exert a justifying effect. Several studies are found in this category, all sharing the common features of disturbances of mitochondrial ROS, ATP or Ca2+ metabolism. They contain cardiovascular diseases (for example atherosclerosis, ischemia/reperfusion injury, heart failure, stroke); aging and neurodegenerative diseases (for example Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia (FRDA)); chronic autoimmune inflammatory diseases (for example rheumatoid arthritis (RA)) ; metabolic diseases(for example diabetes and obesity) ; as well as ionizing radiation injury (Table 1) [6].”

“Small molecule drugs or biologics can act on mitochondria through various pathways. Many of these mechanisms will be argued in more detail in the below sections, and a detailed discussion would immensely encroach the purpose of this chapter, but attractive current approaches include OXPHOS uncoupling, mitochondrial Ca2+ modulation, ETC inhibition and control of oxidative stress through increase or decrease of mitochondrial ROS accumulation.”

[tradeherpete]

Great ponts Xena,

Since Anavex is still a non revenue microcap speculative company it can be managed by the huge forces around it utilizing hedge funds, connections with media etc. We are still in an incubative state and they would like to keep us there until they figure a way to take what we have for themselves.

The stakes are so high, with the CNS space pretty much in the balance. That’s really really big and Anavexs’ potential reaches across to other fields of medicine. The only way to describe it would involve superlative abuse.

Wednesday we get on the big stage side be side with Biogen. Biogen has no choice but to pile on the Press Releases and hype. They have nothing to show next week we haven’t seen for the past 20 years. They will be serving up 3 week old horse pucky. All hype and ballyhoo for show.

Next week Anavex will reveal the stepping stones to a 21st Century Cure for CNS diseases and there is nothing Biogen can do about it.

Let the chips fall where they may.

Go Anavex!

imo

[tredenwater2]

Thanks for reminding me Xena of this. I use to rely McMagyar's emboldened reminder to refocus me on this point. He has been slipping lately ahead of the AAIC.

Yes Missling has built a broad base showing the world only the "tip of the iceberg" as he builds the supporting science through RWE and new precision medicine trials. I dont even pretend to understand half of the synergies of all the cellular communications that get mentioned on this board. I am humbled by the amount of science that is expounded here.

Almost the entire portfolio of CNS and psych drugs (also antibiotics, statins and other drugs) would suddenly need to be quantified for mitochondrial side effects. Ultimately most would go off the market IMO.

Many thanks to all.

Tred